Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorolanib adjuvant monotherapy in intermediate-high risk resectable renal cell carcinoma (Phase II)
ChiCTR2600119252Phase 2Not yet recruiting
- Sponsor
- Chongqing University Cancer Hospital
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vorolanib in clear cell renal cell carcinoma (ccRCC), sponsored by Chongqing University Cancer Hospital. Primary endpoint: 3-year disease-free survival rate. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
vorolanib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on ChiCTR2600119252.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600119252.